Health & Fitness
Mon, February 13, 2012Sun, February 12, 2012Fri, February 10, 2012Thu, February 9, 2012Wed, February 8, 2012Tue, February 7, 2012Mon, February 6, 2012Sun, February 5, 2012Sat, February 4, 2012Fri, February 3, 2012Thu, February 2, 2012Wed, February 1, 2012Tue, January 31, 2012Unigene to Present at the 14th Annual BIO CEO amp;; Investor Conference on February 13, 2012
Published in Health and Fitness on Tuesday, February 7th 2012 at 5:41 GMT by Market Wire
Unigene to Present at the 14th Annual BIO CEO & Investor Conference... -- BOONTON, N.J., Feb. 7, 2012 /PRNewswire/ --
Unigene to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
BOONTON, N.J., Feb. 7, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer will be presenting a corporate overview at the 14th Annual BIO CEO & Investor Conference in New York, NY. Mr. Palmer's presentation is scheduled to begin at 11:00 a.m. ET on Monday, February 13, 2012.
Individuals can listen to a live webcast of the presentation by logging on to the Investors and Media section under the Events tab of the Unigene web site, [ http://www.unigene.com ]. Participants should allow approximately 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Investor Contact
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
[ jthomas@unigene.com ]
Media Contact
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
[ jrando@tiberend.com ] / [ amielach@tiberend.com ]
SOURCE Unigene Laboratories, Inc.
[ Back to top ] RELATED LINKS
[ http://www.unigene.com ]
